3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Head & Neck
2
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
28
Carcinoma, Hepatocellular
25
Colorectal Neoplasms
23
Carcinoma, Non-Small-Cell Lung
13
Melanoma
12
Stomach Neoplasms
10
Colonic Neoplasms
10
Liver Neoplasms
9
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Carcinoma, Transitional Cell
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Prostatic Neoplasms
5
Lung Neoplasms
5
Gastrointestinal Stromal Tumors
5
Esophageal Neoplasms
5
Carcinoma
5
Urinary Bladder Neoplasms
4
Turcot syndrome
4
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma
4
Mesothelioma
4
Endometrial Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Merkel Cell
4
Interventions
pembrolizumab
2
romidepsin
1
montanide ISA 51
1
brostallicin
1
belinostat
1
Trabectedin
1
Sunitinib
1
Ritonavir
1
Radiotherapy
1
Ipilimumab
1
Interleukin-2
1
Indinavir
1
Imatinib Mesylate
1
Histamine H2 Antagonists
1
HhAntag691
1
Fluorouracil
1
Famotidine
1
Angptl4 protein, mouse
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
Ipilimumab
×
Gastrointestinal
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled